Current Pharmacotherapies of Alcoholism: A U.S. Perspective
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Advances in the neurobiology of addiction and improved clinical trial methodology have accelerated the evaluation of medication for alcoholism. While psychosocial interventions have been useful to reduce consumption and support abstinence, considerable improvement in treatment is needed. Medication can play a crucial role in the reduction of craving and drinking and the maintenance of abstinence. This article reviews pharmacotherapy for alcoholism with an emphasis on the perspective of the United States. The opiate antagonist naltrexone, the glutamate modulator acamprosate, and serotonergic agents will be highlighted in this review. In general, both naltrexone and acamprosate have been found in a number of studies to be efficacious agents for the treatment of alcohol dependence. Serotonin reuptake inhibitors have not consistently shown to be efficacious but may be useful in certain subgroups of alcoholics. The serotonin type‐3 antagonist, ondansetron, has shown promise in early‐onset alcoholics but needs more extensive study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999) · JAMA · doi:10.1001/jama.281.14.1318 · Cited by 444
Disulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study
Fuller, R. K. (1986) · JAMA · doi:10.1001/jama.1986.03380110055026 · Cited by 431
Drug therapy for alcohol dependence
Swift, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401907 · Cited by 255
Self-citationBuspirone Treatment of Anxious Alcoholics: A Placebo-Controlled Trial
Kranzler, H. R. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950090052008 · Cited by 248
Streeton, C. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.6.544 · Cited by 228
Cited by
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908
The Development of Alcohol Use Disorders
Sher, K. J., Grekin, E. R., & Williams, N. A. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.144107 · Cited by 469
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451
“W HILE PHARMACOtherapy for alcohol dependence is limited, several drugs have received Food and Drug Administration approval.(1,2) Meta-analyses of many single-site and multisite studies of the opioid antagonist medication naltrexone hydrochloride have suggested that the effect size for response over placebo is in the…”
BackgroundSelf-citationMann, K., Lehert, P., & Morgan, M. Y. (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000108656.81563.05 · Cited by 364
Adolescence: booze, brains, and behavior
Monti, P. M., Miranda, R., Nixon, K., Sher, K. J., Swartzwelder, H. S., Tapert, S. F., White, A., & Crews, F. T. (2005) · Alcoholism: Clinical & Experimental Research · doi:10.1097/01.alc.0000153551.11000.f3 · Cited by 206
Metadata
- Authors
- Anton, R. F., & Swift, R. M.
- Venue
- The American Journal on Addictions
- Publisher
- Wiley
- Published
- 2003-05-06
- Volume
- 12
- Issue
- s1
- Pages
- s53-s68
- ISSN
- 1055-0496 (ISSN-L)
- 1521-0391
- OpenAlex
- W2110857280
- Cited by
- 65
- References
- 7
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Pharmacotherapies of Alcoholism: A U.S. Perspective. https://app.cochat.ai/papers/10.1111/j.1521-0391.2003.tb00496.x
- The paper
- Anton, R. F., & Swift, R. M. (2003). Current Pharmacotherapies of Alcoholism: A U.S. Perspective. The American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2003.tb00496.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.